These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22203601)

  • 1. Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies.
    Matsuzaki J; Suzuki H; Nishizawa T; Hirata K; Tsugawa H; Saito Y; Okada S; Fukuhara S; Hibi T
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1643-5. PubMed ID: 22203601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 10-Year Trends in Helicobacter pylori Eradication Rates by Sitafloxacin-Based Third-Line Rescue Therapy.
    Mori H; Suzuki H; Matsuzaki J; Masaoka T; Kanai T
    Digestion; 2020; 101(5):644-650. PubMed ID: 31387107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies for Helicobacter pylori Strains Containing the gyrA Mutation.
    Mori H; Suzuki H; Matsuzaki J; Tsugawa H; Fukuhara S; Miyoshi S; Hirata K; Seino T; Matsushita M; Masaoka T; Kanai T
    Helicobacter; 2016 Aug; 21(4):286-94. PubMed ID: 26612407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan.
    Hirata Y; Ohmae T; Yanai A; Sakitani K; Hayakawa Y; Yoshida S; Sugimoto T; Mitsuno Y; Akanuma M; Yamaji Y; Ogura K; Maeda S; Koike K
    Int J Antimicrob Agents; 2012 Apr; 39(4):352-5. PubMed ID: 22321702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Helicobacter pylori cure rate with sitafloxacin-based triple therapy.
    Sugimoto M; Sahara S; Ichikawa H; Kagami T; Uotani T; Furuta T
    Aliment Pharmacol Ther; 2015 Aug; 42(4):477-83. PubMed ID: 26075959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen.
    Hirata Y; Serizawa T; Shichijo S; Suzuki N; Sakitani K; Hayakawa Y; Yamada A; Koike K
    Int J Infect Dis; 2016 Oct; 51():66-69. PubMed ID: 27590563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication.
    Nishizawa T; Suzuki H; Nakagawa I; Iwasaki E; Masaoka T; Hibi T
    J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S167-70. PubMed ID: 19120892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations of Helicobacter pylori associated with fluoroquinolone resistance in Korea.
    Lee JW; Kim N; Nam RH; Park JH; Kim JM; Jung HC; Song IS
    Helicobacter; 2011 Aug; 16(4):301-10. PubMed ID: 21762270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin.
    Ono S; Kato M; Nakagawa S; Mabe K; Sakamoto N
    Helicobacter; 2017 Jun; 22(3):. PubMed ID: 28098408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective therapeutic regimens in two South Asian countries with high resistance to major
    Miftahussurur M; Aftab H; Shrestha PK; Sharma RP; Subsomwong P; Waskito LA; Doohan D; Fauzia KA; Yamaoka Y
    Antimicrob Resist Infect Control; 2019; 8():40. PubMed ID: 30815255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan.
    Furuta T; Sugimoto M; Kodaira C; Nishino M; Yamade M; Uotani T; Sahara S; Ichikawa H; Yamada T; Osawa S; Sugimoto K; Watanabe H; Umemura K
    J Gastroenterol Hepatol; 2014 Mar; 29(3):487-93. PubMed ID: 24224808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal.
    Miftahussurur M; Shrestha PK; Subsomwong P; Sharma RP; Yamaoka Y
    BMC Microbiol; 2016 Nov; 16(1):256. PubMed ID: 27809767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution of spontaneous gyrA mutations in 97 fluoroquinolone-resistant Helicobacter pylori isolates collected in France.
    Garcia M; Raymond J; Garnier M; Cremniter J; Burucoa C
    Antimicrob Agents Chemother; 2012 Jan; 56(1):550-1. PubMed ID: 22064536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
    Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
    World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on quinolone-containing rescue therapies for
    Mori H; Suzuki H
    World J Gastroenterol; 2020 Apr; 26(15):1733-1744. PubMed ID: 32351290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoroquinolone resistance in Helicobacter pylori: role of mutations at position 87 and 91 of GyrA on the level of resistance and identification of a resistance conferring mutation in GyrB.
    Rimbara E; Noguchi N; Kawai T; Sasatsu M
    Helicobacter; 2012 Feb; 17(1):36-42. PubMed ID: 22221614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan.
    Sugimoto M; Sahara S; Ichikawa H; Kagami T; Ban H; Otsuka T; Andoh A; Furuta T
    Helicobacter; 2017 Feb; 22(1):. PubMed ID: 27213463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study.
    Pilotto A; Franceschi M; Rassu M; Leandro G; Bozzola L; Furlan F; Di Mario F
    Dig Liver Dis; 2000 Nov; 32(8):667-72. PubMed ID: 11142574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan.
    Hung KH; Sheu BS; Chang WL; Wu HM; Liu CC; Wu JJ
    Helicobacter; 2009 Feb; 14(1):61-5. PubMed ID: 19191898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
    Sue S; Shibata W; Sasaki T; Kaneko H; Irie K; Kondo M; Maeda S
    J Gastroenterol Hepatol; 2019 Apr; 34(4):686-692. PubMed ID: 30151994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.